BTAI   $0.38  -2.56% Market Closed After Close 0.3601 -5.24%

BioXcel Therapeutics Inc
Last Events:

2023-08-09 Trend pattern changed from расширяющийся канал to расходящийся клин с наклоном вниз.

2023-08-09 Signal in MACD changed from bearish recovery to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: main and signal line crossing.

2023-08-05 Trend pattern changed from расходящийся клин с наклоном вниз to расширяющийся канал.

2023-08-05 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-04 Signal in Stochastic changed from bearish recovery to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-08-04 Signal in RSI changed from bearish recovery to bullish reversal. RSI indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the overbought zone.

2023-08-03 Signal in Stochastic changed from bearish weakening to bearish recovery. The stochastic indicator is in the oversold territory and it falls. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: main and signal line crossing.

2023-08-03 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: exit from the oversold zone.


Current temperature: 8.19
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 3.54
Mean unverified/preliminary 3.54 / 3.54
Target Price Low / High 0.25 / 9.00
Median / STD DEV 3.00 / 3.40
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None None ActivelyBuy
rsi ActivelyBuy ActivelyBuy ActivelyBuy
macd ActivelyBuy None None
stoch ActivelyBuy None None
ma20 None ActivelyBuy ActivelyBuy
ma50 ActivelyBuy None None
ma100 Sell Sell ActivelyBuy
Candlestick PatternJan. 3, 2025 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US09075P1057
ceo Dr. Vimal D. Mehta Ph.D.
Website https://www.bioxceltherapeutics.com
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.